The Promise of Precision Medicine

See our latest video: "What If "
   • What If   -~-
Today's conventional technology for measuring cellular mutations and heterogeneity for complex disease is bulk sequencing based on averages. However, the problem with averages is that the underlying genetic diversity is missed across cell populations. Understanding this diversity is important for patient stratification, therapy selection, and disease monitoring. Moving beyond averages helps to deliver on the promise of precision medicine.

Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation to name a few.


Learn more about Mission Bio: https://missionbio.com/

LinkedIn:   / mission-bio  

Twitter:   / missionbio  

Facebook:   / missionbio  

Subscribe to our emails and updates: https://go.missionbio.com/l/552252/20...